Senior Scientific Advisor
“My key focus is to optimize and expand Sinclair’s service offerings as we support an increasingly diverse array of drug development programs for our growing customer base,” Dr. Rogers said. “With fewer CROs than ever offering full-service IND-enabling toxicology and safety pharmacology services, I am excited to be part of a growing company focused on developing new services and supporting sponsor programs.”
Dr. Rogers is well-versed in providing preclinical drug development services to biopharma, NIH and DoD. Prior to joining Sinclair Research, Tina held various leadership positions including Vice President of Preclinical Sciences at Altasciences (formerly SNBL USA), executive vice president and director of Research at MPI Research (now Charles River) and vice president of Drug Development at Southern Research Institute.
Dr. Rogers holds a PhD in Molecular & Cellular Biology and Pathobiology from the Medical University of South Carolina, an MBA from Auburn University and is a diplomate of the American Board of Toxicology. She has a broad technical background including cell biology, immunology, toxicology, cell and gene therapy, sepsis, inflammation, BL-3 and select agents, flow cytometry, and predictive/in vitro toxicology.
“Tina brings a decades-long successful track record of leading growth initiatives and new service development,” said Andy Brown, Vice President of Commercial Operations at Sinclair Research. “Her unique blend of business acumen and scientific expertise will be invaluable as we focus on new service development that delivers real value to our customers as they seek a high quality nonclinical CRO to support their research. I’m excited for the transformational impact Tina will have at Sinclair Research.”